ISSN (Print): 1570-159X
ISSN (Online): 1875-6190
Download PDF Flyer
Open Access Funding
ISSN (Print): 1570-159X
ISSN (Online): 1875-6190
Aims & Scope
Science Citation Index Expanded (SciSearch®), Journal Citation Reports/Science Edition, Neuroscience Citation Index®, BIOSIS Previews, BIOSIS Reviews Reports and Meetings, MEDLINE/PubMed/PubMed Central, Europe PMC, Scopus, EMBASE, Chemical Abstracts Service/SciFinder, ChemWeb, Google Scholar, PsycINFO, ProQuest, Genamics JournalSeek, MediaFinder®-Standard Periodical Directory, PubsHub, Index Copernicus, J-Gate, CNKI Scholar, Suweco CZ, TOC Premier, EBSCO, Ulrich's Periodicals Directory and JournalTOCs.
Ranking and Category:
69 th of 261 in Neurosciences 40 th of 261 in Pharmacology & Pharmacy
Submit Abstracts / Manuscripts Online
T.E. Salt University College London Institute of Ophthalmology London EC1V 9EL UK
View Full Editorial Board
5 - Year: 5.086
Order Your Article Before Print
Self Archiving Policies
Instructions for Authors
Free Copies Online
Open Access Articles
Most Cited Articles
Advertise With Us
Most Accessed Articles
Most Popular Articles
Special Issue Submission
"By providing succinct reviews of recent advances, Current Neuropharmacology will greatly facilitate readers' comprehension of the big picture."
Solomon H. Snyder
Johns Hopkins Univ., USA
GLAUCOMA: IN SEARCH OF BETTER NEUROTHERAPEUTICS
Guest Editor(s): Rossella Russo, Giacinto Bagetta
Tentative Publication Date: July, 2018
Submit Abstract via Email
NICOTINE AND THE NICOTINIC CHOLINERGIC SYSTEM IN HEALTH AND DISEASE
Guest Editor(s): Sakire Pogun
Thank you very much for your mail. Our experience with Bentham Science Publishers has been very positive.
Pedraza Carmen (Departamento de Psicobiologia y Metodologia en las CC, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Malaga, Malaga, Spain.)
Has contributed: Stress, Depression, Resilience and Ageing: A Role for the LPA-LPA1 Pathway
Major advances in our understanding of the neurology/pathology, anatomy/physiology, and molecular biology
of the cerebellum have opened a new door for cerebellar ataxias (CAs). We have now entered in the ‘era of therapies’.
Cures are knocking at the door. We discuss the hot topics in the therapeutic protocols available for CAs, including aminopyridines,
noninvasive cerebellar stimulation, anti-oxidant drugs and therapies for immune-mediated cerbellar ataxias
(IMCAs), topics emphasized in this issue. The history of the cerebellum is a typical example of the importance of apparently
divergent and multi-disciplinary approaches.
Programmed cell death (PCD), referring to apoptosis, autophagy and programmed necrosis
(necroptosis and pyroptosis), plays crucial roles in the pathophysiology of stroke and has always
been the potential therapeutic target. Deciphering PCD signaling pathways helps to
understanding the molecular mechanisms of the brain disorders and promotes discovery of novel
therapeutic targets for stroke treatment.
The aims of this thematic issue are to review the progress of PCD signaling pathways in stroke,
and update the new advance of novel pharmacological and molecular treatment strategies
targeting PCD in the basic science research of stroke, translation and neurobiology of clinical
Eating disorders (anorexia nervosa, bulimia nervosa, binge eating disorder, and related
syndromes) are highly distinctive psychiatric disorders. The peak age of onset is 15–25 years,
a developmentally sensitive time. The average illness duration is about 6 years. Young
women make up the majority of people with anorexia and bulimia nervosa, with binge eating
disorder nearly equally common in both sexes. The prevalence of eating disorder behaviours
is rising in high-income countries, especially in combination with obesity. One in every six or
seven young women has an eating disorder and anorexia nervosa is one of the most common
chronic disorders in adolescence. Mortality rates are almost twice as high for people with
eating disorders as in the general population, and nearly six times higher for people with
anorexia nervosa. To date there is a lack in basic, neurobiologically informed research in
eating disorders. Alongside genetic research, brain imaging might help to elucidate
mechanisms related to brain pathophysiology that drive eating disorder behaviours. There are
also various endocrine alterations in eating disorders, and especially when patients are
underweight. However, such endocrine alterations frequently normalize with weight
restoration, and whether they specifically affect the brains and behaviours of patients with an
eating disorder is uncertain. Thus far pharmacotherapy has a secondary role in the treatment
of eating disorders and should not be considered as a sole or primary intervention
With this special issue on “Psychobiology of eating disorders” leading experts in the field of
eating disorders aim to provide current and up-to-date knowledge with focused and cutting
edge reviews of hot topics in eating disorders research to close the gap of bench to bedside
and facilitate a more individualized and precision medicine therapy approach in the treatment
of eating disorders for the future.
This hot topic issue reviews the most up to date literature dealing with pathophysiology
mechanisms underlying RGC death with the scope to propose new venues for the discovery of better
therapeutics on a rational basis.
Neurodegenerative diseases include Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS),
Parkinson's disease (PD), and Huntington's disease. These diseases involve different aspects of reward
processing (primary rewards, secondary rewards, reward-based learning, and reward-based decisionmaking).
About 70% of the population with 65 years or more are affected by these progressive
neurodegenerative disorders of the central nervous system and characterized by gradual loss of cognitive
function, progressive memory loss, disorientation, language impairment, abnormal behavior, personality
changes, etc Theoretical studies using in silico methods have aided in the process of drug discovery.
Technological advances in the areas of structural characterization, computational science, and molecular
biology have contributed to faster planning of new feasible molecules. Chemoinformatic studies show
that a large fraction of compoundss are “drug-like” or at least, “lead-like” having structural and
physicochemical properties that render them as potential drugs or leads. This thematic issue will bring
together theoretical studies of different methodologies, such as QSAR, docking, chemometric tools,
artificial intelligence and other applied in order to optimize the search for new drugs for the cure and
treatment of neurodegenerative diseases.
Traditionally, neuroscientists regarded glial functions as simply providing physical support
and maintenance for neurons. Thus, in this limited role glia had been long ignored. Recently,
glial functions have been gradually investigated, and increasing evidence has suggested that glial
cells perform important roles in various brain functions. Digging up the glial functions and
further understanding of these crucial cells, and the interaction between neurons and glia may
shed new light on clarifying many unknown aspects including the mind-brain gap, and
conscious-unconscious relationships. It is well known that CNS inflammation and immune
activation play a major role in the pathophysiology of neurodegenerative diseases. Although the
blood-brain barrier is able to protect the CNS from immune activation, it becomes more
permeable during inflammation, which renders the brain vulnerable to infections. A better
understanding of the interaction between inflammatory mediators, such as cytokines, and the
activated immune response, including astrocytes and microglia, is critical for the development of
new therapeutic strategies for neurodegenerative diseases.
The goal of this SI is to review the relationship of neuron-glia and cytokines in the
pathophysiology of neuropsychiatric disorders and the mechanisms of action of drugs used for
their treatment. The SI provides evidences for the role of the inflammation induced toxic
metabolites from the tryptophan pathway in neuropsychiatric disorders such as depression,
schizophrenia, and Alzheimer's disease and so on. A better understanding of the interaction
between cytokines, glia and neurons provide new strategies for the development of novel
therapeutic targets for neuropsychiatric disorders.
This themed issue aims to bring together recent findings in basic and clinical sciences with a
translational perspective that will cover the involvement of the nicotinic cholinergic system not only in
physiological functions but also in disease states, including but not limited to tobacco addiction, as well
as drug development.
No Text Found